Retinoic acid (RA) is a potent epigenetic regulator that directly controls transcription of key genes during development. This article addresses concerns about recently published data suggesting that RA influences the timing and scaling of limb development. RA gain-offunction (GOF) studies in chick embryos where RA is added at pharmacological levels were used to conclude that RA signaling controls the timing and scaling of limb development. However, previous RA loss-of-function (LOF) studies in mouse contradict the conclusions derived from chick GOF studies, instead demonstrating that endogenous RA is not required for timing, scaling, and patterning of limbs during development. As genetic LOF studies are generally considered superior to GOF studies for determining the normal functions of genes, proteins, and signaling molecules (such as RA), readers need to be aware that chick studies do not provide conclusive evidence on the normal function of endogenous RA during limb development.Studies on the mechanisms underlying development of limbs have led to great insight into how epigenetic regulators such as RA control transcription (Cunningham and Duester, 2015). However, studies on how retinoic acid (RA) regulates limb development have been much more controversial. Chick GOF studies have shown that limbs treated with RA have altered proximodistal patterning that forces expression of Meis1/Meis2 to extend from its normal proximal position to a distal position; this observation led to the conclusion that RA normally controls limb proximodistal patterning by activating Meis1/Meis2 in the proximal limb (Mercader et al., 2000;Rosello-Diez et al., 2011). In contrast, mouse RA genetic LOF studies show that RA is not required for limb proximodistal patterning; reviewed in (Cunningham and Duester, 2015). The main problem concerning chick RA GOF studies revolves around the fact that RA is a small molecule that can be added at very high micromolar (μM) levels in GOF studies (Mercader et al., 2000;Rosello-Diez et al., 2011) compared to its normal endogenous levels which are nanomolar (nM) in various tissues of both mouse and chick embryos including limb buds that have ~25 nM RA (Dong and Zile, 1995;Horton and Maden, 1995). In essence, RA added at pharmacological μM levels to embryos or cell lines has side-effects on transcription that allow RA to now control genes that it would not normally control when RA is present at endogenous nM levels (Cunningham and Duester, 2015).Recently, Stainton and Towers (2022) reported studies using chick embryo limb buds treated with pharmacological levels of RA (GOF) or an RA receptor antagonist (to simulate LOF) along with tissue grafting to make the conclusion that RA normally controls the timing and scaling of limb development. In these studies, beads soaked with high levels of RA [0.05 mg/mL; ~0.1 millimolar (mM)] or an RAR antagonist (1 mg/mL; ~2 mM) were